Impact of thrombosis on pulmonary endothelial injury and repair following sepsis

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 312, Issue 4, 2017, Pages L441-L451

  Evans, Colin E ^a   Zhao, You Yang ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Endothelium; Injury; Lung; Repair; Sepsis; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; CELL ADHESION MOLECULE; HYPOXIA INDUCIBLE FACTOR; INTERSTITIAL COLLAGENASE; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; VASCULOTROPIN;

ENDOTHELIUM INJURY; HUMAN; LUNG INJURY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; STIMULATION; THROMBOCYTE; THROMBOSIS; VASCULAR SURGERY; ANIMAL; BIOLOGICAL MODEL; COMPLICATION; PATHOLOGY; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; LUNG INJURY; MODELS, BIOLOGICAL; SEPSIS; THROMBOSIS; WOUND HEALING;

EID: 85017009906     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00441.2016     Document Type: Review

References (142)

1. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238-247, 2003. doi:10.1001/jama.290.2.238.
2. Aeffner F, Bolon B, Davis IC. Mouse models of acute respiratory distress syndrome: a review of analytical approaches, pathologic features, and common measurements. Toxicol Pathol 43: 1074-1092, 2015. doi:10.1177/0192623315598399.
3. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101: 3765-3777, 2003. doi:10.1182/blood-2002-06-1887.
4. Andonegui G, Bonder CS, Green F, Mullaly SC, Zbytnuik L, Raharjo E, Kubes P. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest 111: 1011-1020, 2003. doi:10.1172/JCI16510.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310, 2001. doi:10.1097/00003246-200107000-00002.
6. Bastarache JA, Sebag SC, Clune JK, Grove BS, Lawson WE, Janz DR, Roberts LJ II, Dworski R, Mackman N, Ware LB. Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax 67: 1032-1039, 2012. doi:10.1136/thoraxjnl-2012-201781.
7. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 25: 1545-1550, 2005. doi:10.1161/01.ATV.0000171155.05809.bf.
8. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051-2059, 2001. doi:10.1097/00003246-200111000-00003.
9. Carnemolla R, Villa CH, Greineder CF, Zaitsev S, Patel KR, Kowalska MA, Atochin DN, Cines DB, Siegel DL, Esmon CT, Muzykantov VR. Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31: 761-770, 2017. doi:10.1096/fj.201600912R.
10. Carraway MS, Welty-Wolf KE, Miller DL, Ortel TL, Idell S, Ghio AJ, Petersen LC, Piantadosi CA. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 167: 1200-1209, 2003. doi:10.1164/rccm.200204-287OC.
11. Chen B, Soto AG, Coronel LJ, Goss A, van Ryn J, Trejo J. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Mol Pharmacol 88: 95-105, 2015. doi:10.1124/mol.114.096446.
12. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13: 463-469, 2007. doi:10.1038/nm1565.
13. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166: 98-104, 2002. doi:10.1164/rccm.200109-016OC.
14. de Boer JD, Kager LM, Roelofs JJ, Meijers JC, de Boer OJ, Weiler H, Isermann B, van’t Veer C, van der Poll T. Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia. BMC Infect Dis 14: 559, 2014. doi:10.1186/s12879-014-0559-3.
15. de Stoppelaar SF, van’t Veer C, Claushuis TA, Albersen BJ, Roelofs JJ, van der Poll T. Thrombocytopenia impairs host defense in gramnegative pneumonia-derived sepsis in mice. Blood 124: 3781-3790, 2014. doi:10.1182/blood-2014-05-573915.
16. de Stoppelaar SF, van’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 112: 666-677, 2014. doi:10.1160/TH14-02-0126.
17. Derhaschnig U, Reiter R, Knöbl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102: 2093-2098, 2003. doi:10.1182/blood-2003-02-0416.
18. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT; PROWESS Sepsis Study Group. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90: 642-653, 2003. doi:10.1160/TH02-11-0270.
19. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care 32: 619-629, 2004.
20. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142: 1458-1470, 1993.
21. Eichacker PQ, Gerstenberger EP, Banks SM, Cui X, Natanson C. Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med 166: 1510-1514, 2002. doi:10.1164/rccm.200208-956OC.
22. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166: 1197-1205, 2002. doi:10.1164/rccm.200204-302OC.
23. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer MA, Levy BD. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 6: 256-266, 2013. doi:10.1038/mi.2012.66.
24. Enkhbaatar P, Okajima K, Murakami K, Uchiba M, Okabe H, Okabe K, Yamaguchi Y. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 162: 1752-1759, 2000. doi:10.1164/ajrccm.162.5.9911018.
25. Evans CE, Grover SP, Humphries J, Saha P, Patel AP, Patel AS, Lyons OT, Waltham M, Modarai B, Smith A. Antiangiogenic therapy inhibits venous thrombus resolution. Arterioscler Thromb Vasc Biol 34: 565-570, 2014. doi:10.1161/ATVBAHA.113.302998.
26. Evans CE, Humphries J, Mattock K, Saha P, Smith A. HIF1 signalling regulates venous thrombus resolution. Thromb Res 130: 971-973, 2012. doi:10.1016/j.thromres.2012.08.002.
27. Evans CE, Humphries J, Mattock K, Waltham M, Wadoodi A, Saha P, Modarai B, Maxwell PH, Smith A. Hypoxia and upregulation of hypoxia-inducible factor 1alpha stimulate venous thrombus recanalization. Arterioscler Thromb Vasc Biol 30: 2443-2451, 2010. doi:10.1161/ATVBAHA.110.215038 [Erratum, ArteriosclerThromb Vasc Biol 31: February 2011, p. e5.]
28. Evans CE, Humphries J, Waltham M, Saha P, Mattock K, Patel A, Ahmad A, Wadoodi A, Modarai B, Burnand K, Smith A. Upregulation of hypoxia-inducible factor 1 alpha in local vein wall is associated with enhanced venous thrombus resolution. Thromb Res 128: 346-351, 2011. doi:10.1016/j.thromres.2011.05.006.
29. Evans CE, Humphries J, Waltham M, Saha P, Mattock K, Patel A, Ahmad A, Wadoodi A, Modarai B, Rahman S, Patel Y, Smith A. Protein fragments from the VEGF binding domain of fibronectin are expressed in distinct spatial and temporal patterns during venous thrombus resolution. Thromb Res 130: 281-284, 2012. doi:10.1016/j.thromres.2012.05.006.
30. Evans CE, Wadoodi A, Humphries J, Lu X, Grover SP, Saha P, Smith A. Local accumulation of hypoxia-inducible factor 2 alpha during venous thrombus resolution. Thromb Res 134: 757-760, 2014. doi:10.1016/j.thromres.2014.07.024.
31. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408-416, 2001. doi:10.1056/NEJM200108093450603.
32. Giannarelli C, Alique M, Rodriguez DT, Yang DK, Jeong D, Calcagno C, Hutter R, Millon A, Kovacic JC, Weber T, Faries PL, Soff GA, Fayad ZA, Hajjar RJ, Fuster V, Badimon JJ. Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling. Circulation 130: 1274-1286, 2014. doi:10.1161/CIRCULATIONAHA.114.006614.
33. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 3: 88ps25, 2011. doi:10.1126/scitranslmed.3002011.
34. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 87: 218-223, 2002.
35. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 125: 2898-2907, 2015. doi:10.1182/blood-2015-02-355974.
36. Gu JJ, Chen JB, Zhang JH, Zhang H, Wang SS. Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis. Mol Med Rep 14: 5217-5222, 2016. doi:10.3892/mmr.2016.5891.
37. Han J, Ding R, Zhao D, Zhang Z, Ma X. Unfractionated heparin attenuates lung vascular leak in a mouse model of sepsis: role of RhoA/Rho kinase pathway. Thromb Res 132: e42-e47, 2013. doi:10.1016/j.thromres.2013.03.010.
38. Hirota K. Involvement of hypoxia-inducible factors in the dysregulation of oxygen homeostasis in sepsis. Cardiovasc Hematol Disord Drug Targets 15: 29-40, 2015. doi:10.2174/1871529X15666150108115553.
39. Huang X, Dai Z, Cai L, Sun K, Cho J, Albertine KH, Malik AB, Schraufnagel DE, Zhao YY. Endothelial p110γPI3K mediates endothelial regeneration and vascular repair after inflammatory vascular injury. Circulation 133: 1093-1103, 2016. doi:10.1161/CIRCULATIONAHA.115.020918.
40. Iba T, Gando S, Murata A, Kushimoto S, Saitoh D, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Ikeda T, Ishhikura H, Ueyama M, Ogura Y, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Study Group. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 63: 1093-1098, 2007. doi:10.1097/01.ta.0000251420.41427.d3.
41. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin attenuates leukocyteendothelial interaction and suppresses the increase of intrinsic damageassociated molecular patterns in endotoxemic rats. J Surg Res 187: 581-586, 2014. doi:10.1016/j.jss.2013.10.058.
42. Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care 13: R203, 2009. doi:10.1186/cc8210.
43. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 130: e129-e133, 2012. doi:10.1016/j.thromres.2012.03.021.
44. Jeong SJ, Han SH, Kim CO, Choi JY, Kim JM. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care 17: R97, 2013. doi:10.1186/cc12742.
45. Kager LM, Schouten M, Wiersinga WJ, de Boer JD, Lattenist LC, Roelofs JJ, Meijers JC, Levi M, Dondorp AM, Esmon CT, van’t Veer C, van der Poll T. Overexpression of the endothelial protein C receptor is detrimental during pneumonia-derived gram-negative sepsis (melioidosis). PLoS Negl Trop Dis 7: e2306, 2013. doi:10.1371/journal.pntd.0002306.
46. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Zeerleder SS, Esmon CT, van’t Veer C, van der Poll T. Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). J Thromb Haemost 11: 282-292, 2013. doi:10.1111/jth.12094.
47. Kerschen E, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernandez JA, Griffin JH, Huettner CS, Castellino FJ, Weiler H. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 120: 3167-3178, 2010. doi:10.1172/JCI42629.
48. Komarova YA, Mehta D, Malik AB. Dual regulation of endothelial junctional permeability. Sci STKE 2007: re8, 2007. doi:10.1126/stke.4122007re8.
49. Konecny FA. Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis. J Res Med Sci 15: 348-358, 2010.
50. Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, Kahr WH, Lindemann S, Seizer P, Yost CC, Zimmerman GA, Weyrich AS. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 7: e1002355, 2011. doi:10.1371/journal.ppat.1002355.
51. LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infec Dis 10: 25-31, 2006. doi:10.1016/j.ijid.2005.06.001.
52. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 31, Suppl: S329-S336, 2003. doi:10.1097/01.CCM.0000057912.71499.A5.
53. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 363: 689-691, 2010. doi:10.1056/NEJMcibr1007320.
54. Levi M. The coagulant response in sepsis. Clin Chest Med 29: 627-642, viii, 2008. doi:10.1016/j.ccm.2008.06.006.
55. Levi M. Platelets in sepsis. Hematology 10, Suppl 1: 129-131, 2005. doi:10.1080/10245330512331390177.
56. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost 41: 9-15, 2015. doi:10.1055/s-0034-1398376.
57. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 39: 559-566, 2013. doi:10.1055/s-0033-1343894.
58. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 38, Suppl: S26-S34, 2010. doi:10.1097/CCM.0b013e3181c98d21.
59. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 79: 294-298, 2013.
60. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 8: 1018-1023, 2002. doi:10.1038/nm748.
61. Li X, Li Z, Zheng Z, Liu Y, Ma X. Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-κB signaling pathway. Inflammation 36: 1201-1208, 2013. doi:10.1007/s10753-013-9656-5.
62. Li Y, Sun JF, Cui X, Mani H, Danner RL, Li X, Su JW, Fitz Y, Eichacker PQ. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit Care Med 39: 1104-1112, 2011. doi:10.1097/CCM.0b013e31820eb718.
63. Lindenblatt N, Menger MD, Klar E, Vollmar B. Systemic hypothermia increases PAI-1 expression and accelerates microvascular thrombus formation in endotoxemic mice. Crit Care 10: R148, 2006. doi:10.1186/cc5074.
64. Liu G, Ye X, Miller EJ, Liu SF. NF-κB-to-AP-1 switch: a mechanism regulating transition from endothelial barrier injury to repair in endotoxemic mice. Sci Rep 4: 5543, 2014. doi:10.1038/srep05543.
65. Liu MW, Su MX, Zhang W, Wang YH, Qin LF, Liu X, Tian ML, Qian CY. Effect of Melilotus suaveolens extract on pulmonary microvascular permeability by downregulating vascular endothelial growth factor expression in rats with sepsis. Mol Med Rep 11: 3308-3316, 2015. doi:10.3892/mmr.2015.3146.
66. Löhde E, Raude H, Lück M, Kraas E, Lierse W. Complement activated granulocytes can cause autologous tissue destruction in man. Mediators Inflamm 1: 177-181, 1992. doi:10.1155/S0962935192000279.
67. Luan ZG, Naranpurev M, Ma XC. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 37: 924-932, 2014. doi:10.1007/s10753-014-9812-6.
68. Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, Newman PJ. Endothelial cell PECAM-1 confers protection against endotoxic shock. Am J Physiol Heart Circ Physiol 288: H159-H164, 2005. doi:10.1152/ajpheart.00500.2004.
69. MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 27: 860-873, 2007. doi:10.1592/phco.27.6.860.
70. Malik AB, Fenton JW II. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 18: 193-199, 1992. doi:10.1055/s-2007-1002425.
71. Mao SZ, Ye X, Liu G, Song D, Liu SF. Resident endothelial cells and endothelial progenitor cells restore endothelial barrier function after inflammatory lung injury. Arterioscler Thromb Vasc Biol 35: 1635-1644, 2015. doi:10.1161/ATVBAHA.115.305519.
72. Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 12: CD004388, 2012. doi:10.1002/14651858.CD004388.pub6.
73. Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 12: CD004388, 2012. doi:10.1002/14651858.CD004388.pub5.
74. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554, 2003. doi:10.1056/NEJMoa022139.
75. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295: L379-L399, 2008. doi:10.1152/ajplung.00010.2008.
76. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12: 324-333, 2012. doi:10.1016/j.chom.2012.06.011.
77. Mihajlovic DM, Lendak DF, Draskovic BG, Mikic AS, Mitic GP, Cebovic TN, and Brkic SV. Thrombomodulin is a strong predictor of multiorgan dysfunction syndrome in patients with sepsis. Clin Appl Thromb Hemost 21: 469-474, 2015. doi:10.1177/1076029613508600.
78. Mirza MK, Sun Y, Zhao YD, Potula HH, Frey RS, Vogel SM, Malik AB, Zhao YY. FoxM1 regulates re-annealing of endothelial adherens junctions through transcriptional control of beta-catenin expression. J Exp Med 207: 1675-1685, 2010. doi:10.1084/jem.20091857.
79. Modarai B, Burnand KG, Humphries J, Waltham M, Smith A. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost 93: 801-809, 2005. doi:10.1160/TH04-09-0596.
80. Mullaly SC, Kubes P. The role of TLR2 in vivo following challenge with Staphylococcus aureus and prototypic ligands. J Immunol 177: 8154-8163, 2006. doi:10.4049/jimmunol.177.11.8154.
81. Munoz FM, Hawkins EP, Bullard DC, Beaudet AL, Kaplan SL. Host defense against systemic infection with Streptococcus pneumoniae is impaired in E-, P-, and E-/P-selectin-deficient mice. J Clin Invest 100: 2099-2106, 1997. doi:10.1172/JCI119744.
82. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285, 2008. doi:10.1001/jama.2008.656.
83. Ning F, Wang X, Shang L, Wang T, Lv C, Qi Z, Wu D. Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats. Gene 557: 88-91, 2015. doi:10.1016/j.gene.2014.12.018.
84. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 285: L20-L28, 2003. doi:10.1152/ajplung.00312.2002.
85. Rafii S, Cao Z, Lis R, Siempos II, Chavez D, Shido K, Rabbany SY, Ding BS. Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration. Nat Cell Biol 17: 123-136, 2015. doi:10.1038/ncb3096.
86. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055-2064, 2012. doi:10.1056/NEJMoa1202290.
87. Ribes JA, Ni F, Wagner DD, Francis CW. Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest 84: 435-442, 1989. doi:10.1172/JCI114184.
88. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 112: 460-467, 2003. doi:10.1172/JCI200319523.
89. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939, 2011. doi:10.1016/S0140-6736(11)61613-9.
90. Robboy SJ, Major MC, Colman RW, Minna JD. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol 3: 327-343, 1972. doi:10.1016/S0046-8177(72)80034-0.
91. Ruan QR, Zhang WJ, Hufnagl P, Kaun C, Binder BR, Wojta J. Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF-kappa b pathway. J Vasc Res 38: 13-19, 2001. doi:10.1159/000051025.
92. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 9, Suppl 1: 306-315, 2011. doi:10.1111/j.1538-7836.2011.04318.x.
93. Russell JA. Management of sepsis. N Engl J Med 355: 1699-1713, 2006. doi:10.1056/NEJMra043632.
94. Saha P, Black S, Breen K, Patel A, Modarai B, Smith A. Contemporary management of acute and chronic deep venous thrombosis. Br Med Bull 117: 107-120, 2016. doi:10.1093/bmb/ldw006.
95. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31-41, 2007. doi:10.1111/j.1538-7836.2006.02267.x.
96. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32: 1825-1831, 2004. doi:10.1097/01.CCM.0000138558.16257.3F.
97. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, Van Marck E. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4: 37-43, 2001. doi:10.1023/A:1016611230747.
98. Sandrock CE, Albertson TE. Controversies in the treatment of sepsis. Semin Respir Crit Care Med 31: 66-78, 2010. doi:10.1055/s-0029-1246290.
99. Sansbury BE, Spite M. Resolution of acute inflammation and the role of resolvins in immunity, thrombosis, and vascular biology. Circ Res 119: 113-130, 2016. doi:10.1161/CIRCRESAHA.116.307308.
100. Schouten M, de Boer JD, Kager LM, Roelofs JJ, Meijers JC, Esmon CT, Levi M, van’t Veer C, van der Poll T. The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis. Thromb Haemost 111: 970-980, 2014. doi:10.1160/TH13-10-0859.
101. Schouten M, de Boer JD, van’t Veer C, Roelofs JJ, Meijers JC, Levi M, Conway EM, van der Poll T. The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia. Eur Respir J 41: 935-942, 2013. doi:10.1183/09031936.00015212.
102. Schouten M, van’t Veer C, Poulussen N, Meijers JC, Levi M, Esmon CT, van der Poll T. The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis. Thromb Res 135: 537-543, 2015. doi:10.1016/j.thromres.2014.12.020.
103. Schouten M, van’t Veer C, Roelofs JJ, Gerlitz B, Grinnell BW, Levi M, van der Poll T. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb Haemost 106: 1189-1196, 2011. doi:10.1160/TH11-06-0438.
104. Schouten M, van’t Veer C, van den Boogaard FE, Gerlitz B, Grinnell BW, Roelofs JJ, Levi M, van der Poll T. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 202: 1600-1607, 2010. doi:10.1086/656787.
105. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 129: 290-295, 2012. doi:10.1016/j.thromres.2011.10.013.
106. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361, 2008. doi:10.1038/nri2294.
107. Shaikh FM, Callanan A, Kavanagh EG, Burke PE, Grace PA, McGloughlin TM. Fibrin: a natural biodegradable scaffold in vascular tissue engineering. Cells Tissues Organs 188: 333-346, 2008. doi:10.1159/000139772.
108. Shen B, Zhao X, O’Brien KA, Stojanovic-Terpo A, Delaney MK, Kim K, Cho J, Lam SC, Du X. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 503: 131-135, 2013. doi:10.1038/nature12613.
109. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 107: 543-547, 1983.
110. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB, Kinasewitz G, Lambris JD, Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116: 1002-1010, 2010. doi:10.1182/blood-2010-02-269746.
111. Takahashi Y, Matsutani N, Dejima H, Nakayama T, Okamura R, Uehara H, Kawamura M. Therapeutic potential of recombinant thrombomodulin for lung injury after pneumonectomy via inhibition of highmobility group box 1 in mice. J Trauma Acute Care Surg 81: 868-875, 2016. doi:10.1097/TA.0000000000001208.
112. Tiruppathi C, Freichel M, Vogel SM, Paria BC, Mehta D, Flockerzi V, Malik AB. Impairment of store-operated Ca2+ entry in TRPC4(_/_) mice interferes with increase in lung microvascular permeability. Circ Res 91: 70-76, 2002. doi:10.1161/01.RES.0000023391.40106.A8.
113. Tiruppathi C, Lum H, Andersen TT, Fenton JW II, Malik AB. Thrombin receptor 14-amino acid peptide binds to endothelial cells and stimulates calcium transients. Am J Physiol Lung Cell Mol Physiol 263: L595-L601, 1992.
114. Tiruppathi C, Minshall RD, Paria BC, Vogel SM, Malik AB. Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul Pharmacol 39: 173-185, 2002. doi:10.1016/S1537-1891(03)00007-7.
115. Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, Agarwal A, Covic L, Opal SM, Kuliopulos A. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 3: 370-384, 2011. doi:10.1002/emmm.201100145.
116. Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM; Microcirculatory Alterations in Resuscitation and Shock Investigators. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 49: 88-98, 2007. doi:10.1016/j.annemergmed.2006.08.021.
117. Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. Nebulized anticoagulants for acute lung injury: a systematic review of preclinical and clinical investigations. Crit Care 16: R70, 2012. doi:10.1186/cc11325.
118. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A 106: 19497-19502, 2009. doi:10.1073/pnas.0905325106.
119. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41: 2069-2079, 2013. doi:10.1097/CCM.0b013e31828e9b03.
120. Vogel SM, Gao X, Mehta D, Ye RD, John TA, Andrade-Gordon P, Tiruppathi C, Malik AB. Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice. Physiol Genomics 4: 137-145, 2000.
121. Waltham M, Burnand KG, Collins M, Smith A. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 32: 988-996, 2000. doi:10.1067/mva.2000.110882.
122. Wang T, Liu Z, Wang Z, Duan M, Li G, Wang S, Li W, Zhu Z, Wei Y, Christiani DC, Li A, Zhu X. Thrombocytopenia is associated with acute respiratory distress syndrome mortality: an international study. PLoS One 9: e94124, 2014. doi:10.1371/journal.pone.0094124.
123. Wang Y, Zhao Z, Rege SV, Wang M, Si G, Zhou Y, Wang S, Griffin JH, Goldman SA, Zlokovic BV. 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nat Med 22: 1050-1055, 2016. doi:10.1038/nm.4154.
124. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 291: L307-L311, 2006. doi:10.1152/ajplung.00157.2006.
125. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000. doi:10.1056/NEJM200005043421806.
126. Welty-Wolf KE, Carraway MS, Idell S, Ortel TL, Ezban M, Piantadosi CA. Tissue factor in experimental acute lung injury. Semin Hematol 38, Suppl 12: 35-38, 2001. doi:10.1016/S0037-1963(01)90145-3.
127. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA. Coagulation blockade prevents sepsisinduced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988-1996, 2001. doi:10.1164/ajrccm.164.10.2105027.
128. Welty-Wolf KE, Carraway MS, Ortel TL, Ghio AJ, Idell S, Egan J, Zhu X, Jiao JA, Wong HC, Piantadosi CA. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 290: L21-L31, 2006. doi:10.1152/ajplung.00155.2005.
129. Wiersinga WJ, Meijers JC, Levi M, van’t Veer C, Day NP, Peacock SJ, van der Poll T. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 6: 32-39, 2008. doi:10.1111/j.1538-7836.2007.02796.x.
130. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol 14: 785-792, 2013. doi:10.1038/ni.2631.
131. Xiang B, Zhang G, Guo L, Li XA, Morris AJ, Daugherty A, Whiteheart SW, Smyth SS, Li Z. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 4: 2657, 2013. doi:10.1038/ncomms3657.
132. Yadav H, Kor DJ. Platelets in the pathogenesis of acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 309: L915-L923, 2015. doi:10.1152/ajplung.00266.2015.
133. Yasui H, Donahue DL, Walsh M, Castellino FJ, Ploplis VA. Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury. Am J Physiol Lung Cell Mol Physiol 311: L74-L86, 2016. doi:10.1152/ajplung.00429.2015.
134. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord 15: 130, 2015. doi:10.1186/s12872-015-0124-z.
135. Ye X, Ding J, Zhou X, Chen G, Liu SF. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med 205: 1303-1315, 2008. doi:10.1084/jem.20071393.
136. Yin H, Stojanovic-Terpo A, Xu W, Corken A, Zakharov A, Qian F, Pavlovic S, Krbanjevic A, Lyubimov AV, Wang ZJ, Ware J, Du X. Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol 33: 2529-2537, 2013. doi:10.1161/ATVBAHA.113.302339.
137. Zanardo RC, Bonder CS, Hwang JM, Andonegui G, Liu L, Vestweber D, Zbytnuik L, Kubes P. A down-regulatable E-selectin ligand is functionally important for PSGL-1-independent leukocyte-endothelial cell interactions. Blood 104: 3766-3773, 2004. doi:10.1182/blood-2004-02-0578.
138. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116: 3211-3219, 2006. doi:10.1172/JCI29499.
139. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1100, 1997. doi:10.1097/00003246-199707000-00001.
140. Zhang X, Wang T, Gui P, Yao C, Sun W, Wang L, Wang H, Xie W, Yao S, Lin Y, Wu Q. Resolvin D1 reverts lipopolysaccharide-induced TJ proteins disruption and the increase of cellular permeability by regulating IκBα signaling in human vascular endothelial cells. Oxid Med Cell Longev 2013: 185715, 2013. doi:10.1155/2013/185715.
141. Zhao YD, Huang X, Yi F, Dai Z, Qian Z, Tiruppathi C, Tran K, Zhao YY. Endothelial FoxM1 mediates bone marrow progenitor cellinduced vascular repair and resolution of inflammation following inflammatory lung injury. Stem Cells 32: 1855-1864, 2014. doi:10.1002/stem.1690.
142. Zhao YY, Gao XP, Zhao YD, Mirza MK, Frey RS, Kalinichenko VV, Wang IC, Costa RH, Malik AB. Endothelial cell-restricted disruption of FoxM1 impairs endothelial repair following LPS-induced vascular injury. J Clin Invest 116: 2333-2343, 2006. doi:10.1172/JCI27154.